Vincerx Pharma, Inc.
VINC evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $68K
- Cash Runway:
- 3.0 mo
What it means
What to watch
Prepared research question
What matters most for VINC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VINC
Vincerx Pharma, Inc. (VINC) is a biotech company developing small molecule-drug conjugates and antibody-drug conjugates, currently facing significant capital constraints after unsuccessful fundraising efforts.
Key risk: Insufficient capital
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
Vincerx Pharma, Inc. (VINC) is a biotech company developing small molecule-drug conjugates and antibody-drug conjugates, currently facing significant capital constraints after unsuccessful fundraising efforts.
- Cash & equivalents of $4.4M as of 2025-03-31 [sec].
- Net income of -$5.0M as of 2025-03-31 [sec].
- Shareholders' equity of $2.1M as of 2025-03-31 [sec].
- Raised approximately $16.5 million through a stock and warrant offering in April 2024, below the capital required for continued development [sec · filed 2025-05-12].
- Unsuccessful in raising additional capital or attracting a strategic partner by late 2024 [sec · filed 2025-05-12].
What works
- The company's data was described as 'promising' by potential investors and strategic partners [sec · filed 2025-05-12].
- The company has two active development programs: VIP236 (small molecule-drug conjugate) and VIP943 (anti-CD123 antibody-drug conjugate) [sec · filed 2025-05-12].
What to weigh
- Investors did not view the data as sufficient to support proposed financing, and a capital-raising effort was unsuccessful [sec · filed 2025-05-12].
- The company was unable to raise additional capital or attract a strategic partner through late 2024 [sec · filed 2025-05-12].
- Cash & equivalents of $4.4M as of 2025-03-31 is low relative to the net loss of $5.0M for the period [sec].
- The company implemented cost-cutting measures in early December 2024 due to inability to raise capital [sec · filed 2025-05-12].
From the filings
Quoted directly from source documents.
Investors did not view data as sufficient to support financing.
“Investors did not view the data as sufficient to support the proposed financing, and the capital-raising effort was unsuccessful.”
SEC filings · May 12, 2025
The company raised $16.5 million in April 2024, below required capital.
“the Company raised approximately $16.5 million through a stock and warrant offering. This amount was below the capital required to support the continued development of VIP236 and VIP943.”
SEC filings · May 12, 2025
The company was unsuccessful in raising additional capital or attracting a strategic partner by late 2024.
“the Company continued to engage with prospective investors, focusing on a smaller round of financing, and also continued to aggressively pursue potential strategic partners but was unsuccessful in raising any additional capital or attracting a strategic partner.”
SEC filings · May 12, 2025
Risks & what to watch (3)›
Key risks
- Insufficient capital — Cash of $4.4M as of 2025-03-31 is low relative to net loss of $5.0M, and further fundraising was unsuccessful [sec].
- No strategic partner — Efforts to secure a strategic partner through late 2024 were unsuccessful [sec · filed 2025-05-12].
- Data not sufficient — Investors and partners indicated further clinical responses and extended follow-up data are needed [sec · filed 2025-05-12].
What to watch
- Whether the company can secure any additional financing or a strategic partner in 2025 [sec · filed 2025-05-12].
- Any further clinical data updates for VIP236 or VIP943 that might change investor perception [sec · filed 2025-05-12].
- Cash runway and potential need for further cost-cutting or restructuring [sec].
Sources: Competitor trials · SEC filings · Generated October 3, 2026 · How we verify sources →
Run Vincerx Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vincerx Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
3.0 months
D/E 1.27
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 22, 2026- % of float
- 2.7%
- Days to cover
- 0.1
- Shares short
- 137,204
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VINC short interestFrequently asked questions
What is the AI investment thesis for Vincerx Pharma, Inc.?
Vincerx Pharma, Inc. (VINC) is a biotech company developing small molecule-drug conjugates and antibody-drug conjugates, currently facing significant capital constraints after unsuccessful fundraising efforts.
Who is the CEO of Vincerx Pharma, Inc.?
Dr. Raquel E. Izumi Ph.D. is the chief executive officer of Vincerx Pharma, Inc. (VINC).
Where is Vincerx Pharma, Inc. headquartered?
Vincerx Pharma, Inc. (VINC) is headquartered in San Mateo, CA, United States.
What therapeutic areas does Vincerx Pharma, Inc. focus on?
Vincerx Pharma, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.